Bailard, Inc. Editas Medicine, Inc. Transaction History
Bailard, Inc.
- $3.8 Billion
- Q3 2024
A detailed history of Bailard, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 33,875 shares of EDIT stock, worth $93,833. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,875
Previous 33,875
-0.0%
Holding current value
$93,833
Previous $158,000
27.22%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EDIT
# of Institutions
245Shares Held
56.4MCall Options Held
399KPut Options Held
394K-
Black Rock Inc. New York, NY7.78MShares$21.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.68MShares$18.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.9MShares$13.6 Million0.62% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.35MShares$9.28 Million0.01% of portfolio
-
State Street Corp Boston, MA2.46MShares$6.82 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $190M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...